REAN Foundation

    • Register
    • Login
    • Search
    • Categories
    • Unread
    • Recent
    • Tags
    • Popular
    • Admin

    New Combination Med for Severe Mental Illness Tied to Less Weight Gain

    Mental Health
    2
    2
    21
    Loading More Posts
    • Oldest to Newest
    • Newest to Oldest
    • Most Votes
    Reply
    • Reply as topic
    Log in to reply
    This topic has been deleted. Only users with topic management privileges can see it.
    • N
      Neel last edited by

      Olanzapine plus samidorphan (Lybalvi) vs olanzapine alone is associated with less weight gain while achieving similar clinical outcomes in patients with recent-onset severe mental illness, new research suggests. However, least one expert says the weight difference between the two drugs is of "questionable clinical benefit." Last year, the US Food and Drug Administration (FDA) approved the drug for the treatment of adults with schizophrenia or bipolar I disorder, as a maintenance monotherapy or as either monotherapy or an adjunct to lithium or valproate for acute manic or mixed episodes.

      S 1 Reply Last reply Reply Quote 0
      • S
        sarkarsatarupa @Neel last edited by

        @neel Results showed those given combination treatment gained just over half the amount of weight as those given monotherapy. They were also 36% less likely to gain at least 10% of their body weight during the 12-week treatment period. These findings add to those from the earlier ENGLIGHTEN-2 trial, which included patients with a more established disorder, said lead investigator René S. Kahn, MD, PhD, Icahn School of Medicine at Mount Sinai, New York City.

        1 Reply Last reply Reply Quote 0
        • First post
          Last post